Novo Nordisk A/S $NVO Shares Purchased by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 9.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,336 shares of the company’s stock after acquiring an additional 1,186 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Novo Nordisk A/S were worth $989,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Lockheed Martin Investment Management Co. lifted its stake in Novo Nordisk A/S by 179.4% during the second quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company’s stock worth $2,999,000 after purchasing an additional 27,900 shares in the last quarter. Unified Investment Management purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at $692,000. Acadian Asset Management LLC lifted its stake in Novo Nordisk A/S by 15,919.9% during the 1st quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company’s stock worth $72,523,000 after acquiring an additional 1,038,137 shares in the last quarter. Guild Investment Management Inc. boosted its holdings in Novo Nordisk A/S by 20.7% during the 2nd quarter. Guild Investment Management Inc. now owns 36,995 shares of the company’s stock valued at $2,553,000 after acquiring an additional 6,345 shares during the period. Finally, Norden Group LLC grew its position in Novo Nordisk A/S by 216.3% in the 2nd quarter. Norden Group LLC now owns 96,332 shares of the company’s stock valued at $6,649,000 after acquiring an additional 65,877 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Rothschild Redb raised Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. Jefferies Financial Group began coverage on Novo Nordisk A/S in a report on Monday, October 27th. They issued an “underperform” rating for the company. UBS Group lowered shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 5th. Finally, BMO Capital Markets reissued a “market perform” rating and set a $55.00 price objective (up previously from $50.00) on shares of Novo Nordisk A/S in a report on Tuesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $59.20.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $49.12 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The company has a 50-day moving average price of $54.69 and a 200 day moving average price of $61.14. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $112.52. The company has a market cap of $219.32 billion, a P/E ratio of 13.49, a PEG ratio of 2.33 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. The company had revenue of $11.74 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.